New Alzheimer's drugs, including Lecanemab and Donanemab, which were initially met with high hopes, have disappointed in a recent study, showing more risks than benefits.

A research team has confirmed the safety of the Alzheimer's drug Lecanemab after examining health data from 2,672 patients 28 weeks into treatment.